Skip to content

Neurim v Mylan: no issue estoppel on divisional arises but English court takes practical case management approach to avoid re-trial

Author
Allos Rafi
Rafi Allos

Partner

London

View profile →

Currie Erin
Erin Currie

Senior Associate

London

View profile →

22 February 2022

On 24 January 2022, Mr Justice Meade handed down the latest main judgment in the ongoing litigation between Neurim (and Flynn) and Generics (UK) Ltd (trading as Viatris but formerly trading as Mylan), which has swiftly been followed by a further short judgment from Mr Justice Marcus Smith.

While no issue estoppel arose on the facts of this case, the Court nonetheless recognised the importance of avoiding a costly full, further trial of issues that had already been litigated between the same parties. Meade J’s approach of managing the situation by sending the case back to Marcus Smith J illustrates an approach which could potentially be applied in future cases involving divisional patents. The court’s flexibility has also meant that Neurim has been able to preserve the possibility of obtaining a final injunction based on its divisional in the very short window before patent expiry, although this will depend on whether Mylan is successful in seeking permission to appeal directly from the Court of Appeal.

A more detailed case summary is available on request, including a deeper dive into issue estoppel, abuse of process and the approach to case management. Please get in touch with one of our team members if you would like to read the full summary and/or discuss the case in further detail.

Related expertise